Novartis: Danish collaboration was an obvious choice
Swiss drug group Novartis is increasing its focus on the Danish market, most recently with a deal with Innovation Fund Denmark, and the company expects it to lead to additional investments in clinical trials in the country.
BY STEFAN SINGH KAILAY
First Novartis struck a five-year deal with the Capital Region of Denmark, and then followed a collaboration agreement with a slew of Danish players through the Innovation Fund Denmark’s Next partnerships.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck: Regions prioritize clinical research
For abonnenter
Here is why Roche opted for Danish partnership
For abonnenter
Novartis strikes deal with Danish region
For abonnenter
